PATHOPHYSIOLOGY AND CLINICAL MANAGEMENT OF ALCOHOLIC LIVER DISEASE

Online Live Event

DIGITAL
An application has been made to the UEMS EACCME® for CME accreditation of this event.
Dear friends and colleagues,

It is our great pleasure to invite you to the Symposium 227 „PATHOPHYSIOLOGY AND CLINICAL MANAGEMENT OF ALCOHOLIC LIVER DISEASE“, organized by the Falk Foundation e.V. that will take place from January 27th until January 28th, 2022 preceding the 38th Annual Meeting of the German Association for the Study of the Liver (GASL). Originally planned as a face to face symposium in Mannheim, the event had to be reorganized as a virtual event due to the ongoing pandemic.

Alcoholic Liver Disease (ALD) – throughout decades due to the label of self-infliction a neglected disease and heavily underfunded clinical research entity – recently gained more public and research interest, probably due to the major advances in the clinical management of Hepatitis B and C, to the alarming increase in alcohol consumption in emerging countries, and in the context of risky social drinking in the upper class. In parallel, however, a continuously increasing attention from research funding sources and pharmaceutical industry is given to NAFLD, which is termed “the epidemic of the 21st century”, thus again pushing ALD behind from the foreground.

Although NAFLD is already affecting about a quarter of the adult population and needs attention, in most cases it is responsible for mild disease courses, whereas severe morbidity and mortality from liver disease is still mostly based on ALD. Aiming to (re)sensitize to the strong need for an academic and clinical focus on ALD, we set up this program and are very happy to present a list of renowned experts prone to provide to us the most recent cutting-edge knowledge on ALD. We have spanned the bow from liver damage and disease initiation – to – fibrosis and disease progression –, including inflammatory phenotyping and molecular profiling at cellular and molecular levels, towards end stage disease – alcoholic hepatitis, liver failure and systemic disturbance – with an outlook on possibilities of intervention.

Complementary to the oral presentations, there will be accompanying poster session on the first day. The symposium will be followed by the annual meeting of the GASL, to which you are also cordially invited.
We thank all the speakers and participants of this symposium for taking the time to share their contributions and opinions on the variant aspects of ALD. We are looking forward to an excellent symposium that will provide a comprehensive course on the variant aspects of ALD and hopefully open doors for new projects and collaborations.

Last but not least, we are most grateful to the Falk Foundation for the generous support of this event.

We wish you a most enjoyable and insightful meeting and very much look forward to welcoming you online.

Steven Dooley
GASL President 2021/2022

with Jonel Trebicka and Sebastian Mueller
January 27-28, 2022

Scientific Organization:
Prof. Dr. Steven Dooley
Department of Medicine II
Medical Faculty Mannheim
At Heidelberg University
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
Germany
Telephone: +49 621 383-3768
E-mail: steven.dooley@medma.uni-heidelberg.de

Scientific Co-Organization:
Sebatian Mueller, Heidelberg (Germany)
Jonel Trebicka, Frankfurt (Germany)

The times in the program are given in UTC.
Please check your local time, e.g. Germany UTC+1.
### Thursday, January 27 2022
(13:30 – 15:05 UTC)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Welcome</td>
</tr>
<tr>
<td></td>
<td><em>Steven Dooley, Mannheim</em></td>
</tr>
<tr>
<td>13:35</td>
<td>Introduction to the topic</td>
</tr>
<tr>
<td></td>
<td><em>Richard Moreau, Paris</em></td>
</tr>
<tr>
<td>13:40</td>
<td>Molecular profiling of alcoholic hepatitis</td>
</tr>
<tr>
<td></td>
<td><em>Ramon Bataller, Pittsburgh</em></td>
</tr>
<tr>
<td>13:55</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>14:00</td>
<td>Immune dysfunction in alcoholic liver disease</td>
</tr>
<tr>
<td></td>
<td><em>Shilpa Chokshi, London</em></td>
</tr>
<tr>
<td>14:15</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>14:20</td>
<td>Inflammation and therapeutic concepts in alcoholic hepatitis</td>
</tr>
<tr>
<td></td>
<td><em>Bin Gao, Bethesda</em></td>
</tr>
<tr>
<td>14:35</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>14:40</td>
<td>Impact of the gut on alcoholic liver disease progression and severe alcoholic hepatitis</td>
</tr>
<tr>
<td></td>
<td><em>Bernd Schnabl, San Diego</em></td>
</tr>
<tr>
<td>14:55</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>15:00</td>
<td>Summary &amp; End of the session</td>
</tr>
<tr>
<td></td>
<td><em>Felix Stickel, Zurich</em></td>
</tr>
</tbody>
</table>
**Thursday, January 27 2022**
(15:05 – 16:00 UTC)

**POSTER SESSION**

*Chairs: Steven Dooley, Mannheim; Sebastian Mueller, Heidelberg; Jonel Trebicka, Frankfurt*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td>Steven Dooley, Mannheim</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session B:</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td>Sebastian Mueller, Heidelberg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session C:</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td>Jonel Trebicka, Frankfurt</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session D:</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:05</td>
<td>N.N.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Q&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:50</td>
<td></td>
</tr>
</tbody>
</table>

*The authors of accepted posters will present their poster in 2-3 minutes. Afterwards there is time for discussion or questions.*

<table>
<thead>
<tr>
<th>Time</th>
<th>Break</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td></td>
</tr>
</tbody>
</table>
### SESSION II
Alcoholic hepatitis, liver failure and systemic disturbance

**Chairs:** Jonel Trebicka, Frankfurt

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:10</td>
<td>Introduction to the topic</td>
<td>Jonel Trebicka</td>
<td>Frankfurt</td>
</tr>
<tr>
<td>16:15</td>
<td>Clinics of severe alcoholic hepatitis and liver transplantation</td>
<td>Alexandre Louvet</td>
<td>Lille</td>
</tr>
<tr>
<td>16:30</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:35</td>
<td>Systemic (mis)communication in severe alcoholic hepatitis and ACLF</td>
<td>Richard Moreau</td>
<td>Paris</td>
</tr>
<tr>
<td>16:50</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:55</td>
<td>Novel drugs for management of acute alcoholic hepatitis</td>
<td>Vijay Shah</td>
<td>Rochester</td>
</tr>
<tr>
<td>17:10</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td>Mechanisms of recovery from and strategies for survival of severe</td>
<td>Rajiv Jalan</td>
<td>London</td>
</tr>
<tr>
<td></td>
<td>alcoholic hepatitis and ACLF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:35</td>
<td>Summary &amp; End of the session</td>
<td>Jonel Trebicka</td>
<td>Frankfurt</td>
</tr>
<tr>
<td>17:40</td>
<td>Closing words</td>
<td>Steven Dooley</td>
<td>Mannheim</td>
</tr>
</tbody>
</table>
Friday, January 287 2022
(08:00 – 11:30 UTC)

08:00  Welcome  
*Steven Dooley, Mannheim*

**SESSION III**  
Liver damage and disease initiation

**Chairs:** *Sebastian Mueller, Heidelberg*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:05</td>
<td>Introduction to the topic</td>
<td><em>Sebastian Mueller, Heidelberg</em></td>
</tr>
<tr>
<td>08:10</td>
<td>Early alcoholic stress to the liver - damage vs steatosis</td>
<td><em>Alexander Krag, Odense</em></td>
</tr>
<tr>
<td>08:25</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>Cellular stress and cell death mechanisms</td>
<td><em>Sophie Lotersztajn, Paris</em></td>
</tr>
<tr>
<td>08:45</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>08:50</td>
<td>Genetic susceptibility for adverse alcohol effects towards liver</td>
<td><em>Felix Stickel, Zurich</em></td>
</tr>
<tr>
<td>09:05</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>09:10</td>
<td>Pathomorphology of alcoholic liver disease progression</td>
<td><em>Tania Roskams, Leuven</em></td>
</tr>
<tr>
<td>09:25</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>Summary &amp; End of the Session</td>
<td><em>Sebastian Mueller</em></td>
</tr>
<tr>
<td>09:35</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
SESSION IV
Fibrosis and disease progression to cirrhosis

Chairs: Steven Dooley, Mannheim

10:00 Introduction to the topic
Steven Dooley, Mannheim

10:05 Architectural and vascular disturbance of liver disease progression
Jan G. Hengstler, Dortmund

10:20 Q&A

10:25 Stratification of cirrhosis and its impact on liver carcinogenesis
Massimo Pinzani, London

10:40 Q&A

10:45 Cell biology of nonparenchymal cells in ALD - repair, disease progression and carcinogenesis
Robert F. Schwabe, New York

11:00 Q&A

11:05 Alcohol mediated modulation of the matrisome and consequences
Gavin E. Arteel, Pittsburgh

11:20 Q&A

11:25 Summary & End of the Session
Steven Dooley, Mannheim

11:30 Closing words
Steven Dooley, Mannheim
LIST OF SPEAKERS, MODERATORS AND SCIENTIFIC ORGANIZERS

Gavin E. Arteel, PhD, FAASLD
Professor of Medicine
Division of Gastroenterology, Hepatology and Nutrition
University of Pittsburgh
S414 Biomedical Science Tower
200 Lothrop St.
Pittsburgh, PA 15261
USA
gearteel@pitt.edu

Ramon Bataller, MD, PhD
Chief of Hepatology
Division of Gastroenterology, Hepatology and Nutrition
University of Pittsburgh
S414 Biomedical Science Tower
200 Lothrop St.
Pittsburgh, PA 15261
USA
bataller@pitt.edu

Dr. Shilpa Chokshi
Chief Scientific Officer
Institute of Hepatology
Honorary Reader in Hepatology
Kings College London
Foundation for Liver Research
111 Coldharbour Lane
London SE5 9NT
Great Britain
s.chokshi@researchinliver.org.uk

Prof. Dr. Steven Dooley
Head of Section Molecular Hepatology
Department of Medicine II
UMM Universitätmedizin Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
Germany
steven.dooley@medma.uni-heidelberg.de

Bin Gao, MD, PhD
Senior Investigator
Laboratory of Liver Diseases
National Institutes of Health
5625 Fishers Lane, Room 2S-33
Bethesda, MD 20892
USA
bgao@mail.nih.gov

Prof. Dr. Jan G. Hengstler
Leibniz Research Centre for Working Environment and Human Factors IfADo
Ardeystr. 67
44139 Dortmund
Germany
hengstler@ifado.de

Prof. Dr. Rajiv Jalan
Royal Free Hospital
School of Medicine
Institute of Hepatology
Rowland Hill Street
London NW3 2PF
Great Britain
r.jalan@ucl.ac.uk

Aleksander Krag, MD, PhD, MBA
Professor and Head of Hepatology
Department of Gastroenterology and Hepatology
University of Southern Denmark & Odense University Hospital
Campusvej 55
5230 Odense
Denmark
aleksander.krag@rsyd.dk

Sophie Lotersztajn, MD, PhD
Director of Research
Deputy Director Center for Research on Inflammation INSERM U1149
Université de Paris
Paris
France
sophie.lotersztajn@inserm.fr
Alexandre Louvet  
Service des maladies de l'appareil digestif  
Hôpital Huriez  
Rue Polonovski  
59037 Lille cedex  
France  
alexandre.louvet@chru-lille.fr

Prof. Dr. Richard Moreau  
Center for Research on Inflammation  
INSERM U1149  
Université de Paris  
Paris  
France  
richard.moreau@inserm.fr

Prof. Dr. Sebastian Mueller  
Director, Center for Alcohol Research, University of Heidelberg  
Vice Head, Department of Internal Medicine, Salem Medical Center Heidelberg  
Zeppelinstr. 11-33  
69121 Heidelberg  
Germany  
sebastian.mueller@urz.uni-heidelberg.de

Massimo Pinzani, MD, PhD  
UCL Insitute for Liver and Digestive Health  
Royal Free Hospital U3  
Pond Street  
London NW3 2QG  
Great Britain  
m.pinzani@ucl.ac.uk

Tania Roskams, MD, PhD  
Catholic University of Leuven  
University Hospital St. Rafael  
Department of Pathology  
Minderbroederstraat 12  
3000 Leuven  
Belgien  
tania.roskams@gmail.com

Prof. Dr. Bernd Schnabl  
UCSD School of Medicine  
Division of Gastroenterology  
Department of Medicine  
University of California  
9500 Gilman Drive  
La Jolla CA 92093  
USA  
beschnabl@health.ucsd.edu

Prof. Dr. Robert F. Schwabe  
Columbia University  
Irving Cancer Research Center  
Department of Medicine  
1130 St. Nicholas Avenue  
New York NY 10032  
USA  
rfs2102@cumc.columbia.edu

Vijay Shah, MD  
Professor of Medicine  
Mayo Clinic  
GI Research Unit  
Alfred 2-435  
200 First Street SW  
Rochester MN 55905  
USA  
shah.vijay@mayo.edu

Prof. Dr. Felix Stickel  
FMH Hepatologie / FMH Gastroenterologie  
Hirslanden Bern AG  
Klinik Beau-Site  
Schänzlihalde 11  
3013 Bern  
Switzerland  
felix.stickel@hirslanden.ch

Prof. Dr. Jonel Trebicka  
Innere Medizin I  
Universitätsklinikum Frankfurt  
Theodor-Stern-Kai 7  
60596 Frankfurt  
Germany  
jonel.trebicka@kgu.de
1. Gender-related differences in response to DUAL diet in murine model of steatohepatitis
   R. Benede-Ubieto, O. Estevez-Vazquez, M. Dumartin, J. Reissing, T. Bruns, J. Vaquero,
   C. Liedtke, C. Trautwein, R. Banares, F. Cubero, Y. Nevzorova (Madrid, ES, Aachen, DE)

2.* Variants APOE (rs429358) and TM6SF2 (rs187429064) modify the risk of hepatocellular
   carcinoma
   S. Buch, H. Innes, H. Nischalke, K. Weiss, D. Gotthardt, J. Rosendahl, F. Lammert, S. Mueller,
   T. Berg, J. Hampe, F. Stickel (Dresden, Bonn, Heidelberg, Halle Saale, Homburg, Leipzig,
   DE, Glasgow, GB, Zurich, CH)

3. H2O2-mediated autophagy during ethanol metabolism

4. In vitro erythrophagocytosis model to study alcohol-mediated heme turnover
   C. CHEN, S. Wang, J. Mueller, S. Mueller (Heidelberg, DE)

5. Collecting clinical data during Covid 19 Pandemic: survey on alcohol consumption in
   patients affected by Chronic Autoimmune Liver Diseases.
   M. Delle Monache, M. Carli, L. Nosotti (Rome, IT)

6. Role of bone morphogenetic protein 6 in hepatocellular carcinoma
   U. Eisner, J. Sommer, A. Bosserhoff, C. Hellerbrand (Erlangen, DE)

7. Non-alcoholic Fatty Liver Disease and Insulin Resistance among patients with Type I
   and Type II Diabetes
   M. Elkady (Benha, EG)

8. Serum Vitamin D in Patients with Non Alcoholic Fatty Liver Disease
   M. Elkady (Benha, EG)

9. A short-term diet withdrawal ameliorates steatohepatitis in DUAL-fed mice
   O. Estevez Vazquez, O. Estevez Vazquez, R. Benede-Ubieto, J. Reissing, T. Bruns,
   J. Vaquero, C. Liedtke, C. Trautwein, R. Banares, F. Javier Cubero, Y. A. Nevzorova
   (Madrid, ES, Aachen, DE)

10. Dysfunctional inducibility of cytokine secretion in T cells of acute-on-chronic liver failure
    patients is accompanied by reduced signalling of important transcription factors
    S. Guckenbiehl, M. Langer, H. Schmidt, C. Lange (Essen, München, DE)

11.* Protective role of prostaglandin E2 in diet-induced steatohepatitis
    J. Henkel-Oberlaender, C. Coleman, S. Kuipers, M. Vahrenbrink, K. Joehrens, T. Weiss,
    G. Pueschel (Kulmbach, Nuthetal, Dresden, Regensburg, DE)

12. Role of endurance training in diet-induced steatohepatitis in rats
    J. Henkel-Oberlaender, K. Buchheim-Dieckow, J. Castro, T. Laeger, K. Joehrens,
    G. Pueschel (Kulmbach, Nuthetal, Dresden, DE)

13.* Alcohol abstinence improves survival in alcohol-related cirrhosis – even in patients who
    have already progressed to high-risk portal hypertension
    B. Hofer, B. Simbrunner, L. Hartl, M. Jachs, L. Balcar, R. Paternostro, P. Schwabl, G. Semmler,
    B. Scheiner, A. Staetttermayer, M. Trauner, M. Mandorfer, T. Reiberger (Vienna, AT)

14. MicroRNAs modulate SARS-CoV-2 infection in primary human hepatocytes by regulating
    the entry factors ACE2 and TMPRSS2
    R. Khanal, N. Heinen, A. Bogomolova, H. Wedemeyer, M. Ott, S. Pfaender, A. Sharma
    (Hannover, Bochum, DE)
15. mRNA therapeutics for liver diseases: HNF4A mRNA delivery via lipid nanoparticles attenuates liver fibrosis in preclinical models
   R. Khanal, T. Yang, M. Poenisch, R. Taubert, B. Engel, E. Jaeckel, T. Cantz, F. Chevessier, A. Balakrishnan, M. Ott, A. Sharma (Hannover, Tübingen, DE)

16. Oral probiotic administration influences pro- and anti-inflammatory cytokines in alcoholic liver disease

17. Rat model of advanced non-alcoholic Steatohepatitis Cirrhosis developing Acute-on-Chronic-Liver failure

18. Rat model of alcoholic liver cirrhosis developing Acute-on-Chronic-Liver failure

19. Rat Model of Cholestatic Liver Cirrhosis Developing Acute-on-Chronic-Liver failure

20. A severity-dependent increase of Yes-associated protein expression in liver biopsy tissues from patients with various stages of alcoholic liver disease
    Y. Liang (Essen, DE)

21.* Survival in a 10 year prospective cohort of heavy drinkers: Liver stiffness is the best long-term prognostic parameter

22.* The role of PNPLA3, MBOAT7 and TM6SF2 during alcohol detoxification: different mechanisms of fibrosis and steatosis development

23. Deep characterization of the non-alcoholic/alcoholic steatohepatitis in liver specimen demonstrated a specific in-situ immunophenotype: a single center experience.
    D. Neureiter, E. Klieser, B. Neumayer (Salzburg, AT)

24. Association between socioeconomic factors and harmful drinking among immigrants in Rome
    L. Nosotti (ITALIA (IT), IT)

25. Expression of Bone Morphogenetic Protein 13 in hepatic stellate cells and hepatic fibrosis
    V. Peschl, T. Seitz, C. Hellerbrand (Erlangen, DE)

26. Serum proteomics predicts the course of alcoholic hepatitis

27. Hepatic Th2 immune response correlates inversely with the egg load in parasitic infection
    L. Russ, V. Von Buelow, L. Hehr, S. Wrobel, V. Wirth, K. Tabatabai, G. Schramm, T. Quack, C. Grevelding, M. Roderfeld, E. Roeb (Gießen, Giessen, Borstel, DE)
28. Expression of paracrine fibroblast growth factors in liver fibrosis
T. Seitz, K. Freese, W. Thasler, C. Hellerbrand (Erlangen, Planegg/Martinsried, DE)

29. Transient elastography in community alcohol services: can it detect significant liver disease and impact drinking behaviour?
A. Sheth, M. Subhani, R. Scott, D. Harman, E. Wilkes, M. James, G. Aithal, S. Ryder, I. Guha (Nottingham, GB)

30. Sexual dimorphism in Western-type diet-induced alterations of lipid and bile acid metabolisms in mice
J. Sommer, G. Liebisch, C. Hellerbrand (Erlangen, Regensburg, DE)

31.* Liver endothelial cells induce hepatocellular carcinoma via Hgf secretion
M. Steffani, J. Wang, C. Stoess, H. Friess, C. Mogler, N. Hueser, D. Hartmann (München, Munich, DE)

32. Liver transplant candidates without 6 months alcohol abstinence: clinical and psychological characteristics
M. Sterneck, C. Lienau, A. Buchholz, D. Eickhoff, A. Harberts, P. Huebener, D. Ruether (Hamburg, DE)

33. Does the host’s age influence the effectivity of Schistosoma mansoni infection?
J. Strassmann, V. Von Buelow, S. Wrobel, C. Grevelding, T. Quack, K. Kernt (Gießen, DE)

34.* Alcohol-related liver disease mortality and missed opportunities: a UK retrospective observational study
M. Subhani, R. Elleray, J. Bethea, J. Morling R, S. Ryder D (Ng7 2uh, Nottingham, GB)

35. Lipid metabolism in non-alcoholic and alcoholic liver disease
A. Sydorchuk, L. Sydorchuk, V. Stepan, I. Sydorchuk, N. Stepan, I. Sydorchuk, I. Hryhorchuk, R. Knut, O. Plehutsa, R. Sydorchuk (Chernivtsi, UA, Siegen, DE)

36. Comparing gut microbiota changes in NAFLD and alcoholic liver disease

37. Ursodeoxycholic acid in alcoholic liver disease

38. Subclassification of human hepatic hemangiomas reveals cellular and functional heterogeneity
S. Thomann, S. Sprengel, J. Liermann, M. Toth, C. Sticht, P. Schirmacher (Heidelberg, Mannheim, DE)

39. Janus kinase 2 inhibition by pacritinib is a potential therapeutic target for liver fibrosis and portal hypertension

40. Metabolomic analysis of bacterial infection markers in blood samples of patients with decompensated liver cirrhosis infused with the novel drug VS-01

41. Evidence for alcohol-mediated masked hemolysis in ALD patients and a vicious cycle of hemolysis and iron-mediated liver damage
42. Liver iron overload in alcoholic liver disease: crosstalk between endothelial cells and hepatocytes in iron regulation

43. Functional activation of the insulin-like growth factor 1 receptor IGF1-R and insulin receptor IR following stimulation with parasite antigens
V. Wirth, V. Von Buelow, L. Hehr, L. Russ, A. Baier, G. Schramm, T. Quack, C. Grevelding, M. Roderfeld, E. Roeb (Giessen, Borstel, DE)

44. Infection grade determines intestinal immune reaction in parasitic infection
S. Wrobel, L. Russ, V. Von Buelow, T. Quack, C. Grevelding, M. Roderfeld, E. Roeb (Gießen, Giessen, DE)

45. Efficacy of endoscopic “micro foam” sclerotherapy in acute varicose bleeding from the veins of the esophagus and stomach in patients with alcoholic liver disease
K. Yaroshenko (Dnipro, UA)

46. The gut microbiome controls liver regeneration through lipid metabolism

* poster of distinction
REGISTRATION

You can register for the event via our homepage: www.falkfoundation.org

Registration is only possible online.

You will receive an automatic confirmation of registration by e-mail. Please do also check you spam folder.

CONGRESS FEES

The Online Event is free of charge.

CONFLICTS OF INTEREST

Members of the scientific committee declare the following potential conflicts of interest:

Jonel Trebicka: Versatis, Gore Medical, Grifols, CSL Behring, MSD, Falk, Norgine

Steven Dooley and Sebastian Mueller declare no potential conflicts of interest.
Registration via www.falkfoundation.org
or simply scan and participate.